Dr. Mohsen Daneshtalab
Professor of Medicinal Chemistry
Associate Dean, Graduate Studies and Research
Phone: 709 777 6958
Individuals interested in pursuing graduate programs (MSc and PhD) under Dr. Daneshtalab’s supervision are required to have a strong background in organic synthesis, both theoretical and hands on experience.
Design, discovery, and development of anti-infectious and anti-tumor agents with natural or synthetic origin
Cancer and infectious diseases are ranked second and third, after cardio-vascular diseases, based on their mortality/morbidity rates, worldwide.
Despite the availability of clinically useful drugs for the treatment of these diseases, the multidrug-resistance, unwanted adverse-reactions, and economical feasibility are the major barriers in their development and clinical application.
The objective of our research is the discovery and development of novel small molecules with potential effect against systemic and invasive microbial infections and wide range of cancers.
Our approaches comprise of identification of the lead biologically active compound via computer-assisted design of novel molecules or biological screening of medicinal plants or marine products.This would be followed by synthesis and biological evaluation.
Through this process, lead compound(s) will be identified which after structural optimization and relevant in vitro/in vivo evaluation a pre-clinical candidate compound will be identified.
Through extensive animal studies and evaluation of clinical potential of this candidate, the clinical candidate will be selected.
Presently, we have identified lead compounds in both areas of infectious diseases and cancer with potential of commercial development.
Our research group has a track record of drug development in collaboration with pharmaceutical industries and that enables us to translate the above research into commercial product.
Key words: Anti-infectious, anticancer, discovery, synthesis, biological evaluation, development
List of Selected Publications since 2004
- C-M. Ma, T. Abe, T. Komiyama, M. Hattori, W. Wang, and, M. Daneshtalab (2010). Synthesis, Anti-fungal and 1,3-β-D-Glucan Synthase Inhibitory Activities of Caffeic and Quinic Acid Derivatives. Bioorg. Med. Chem., 18, 7009
- C-M. Ma, T. Kawahata, M. Hattori, T. Otake, L. Wang, and M. Daneshtalab (2010). Synthesis, anti-HIV and anti-oxidant activities of caffeoyl 5,6-anhydroquinic acid derivatives. Bioorg Med Chem, 18, 863
- C. Ma, M. Hattori, M. Daneshtalab, L. Wang (2008). Chlorogenic Acid Derivatives With Alkyl Chains of Different Lengths and Orientations: Potent α-Glucosidase Inhibitors. J Med Chem, 51 (19), 6188
- C-M. Ma, H-B. Chen, M. Hattori, S-Q. Cai, and M. Daneshtalab (2008)- Profiling the Phenolic Compounds of Artemisia pectinata by HPLC-PAD-MS. Phytochem Anal, 19, 294
- M. Daneshtalab (2008)- Discovery of Chlorogenic Acid-Based Peptidomimetics as a Novel Class of Antifungals. A Success Story in Rational Drug Design. J Pharm Pharmaceut Sci, 11 (2): 44s-55s (www.cspsCanada.org)
- C. Ma, L. Winsor, and M. Daneshtalab (2007). Quantification of Spiroether Isomers and Herniarin of Different Parts of Matricaria matricarioides and Flowers of Chamaemelum nobile. Phytochem. Analysis, 18, 42
- M. Daneshtalab (2006). Novel Synthetic Antibacterial Agents. In Topics in Heterocyclic Chemistry Series, Vol.2. H. M. Lee Volume Editor. Springer-Verlag Publisher. PP., 153-206
- C. Ma, S. Takeda, S. Hibino, and M. Daneshtalab (2006). Synthesis of Peptidomimetic Analogues of Echino-candins. Heterocycles, 68, 721
- S. Rasoul-Amini, A. Khalaj, A. Shafiee, M. Daneshtalab, A. Madadkar-Sobhani, S. Foulddel, E. Azizi (2006). Antitumor Activity of New Quinoline Derivatives in Human Breast Cancer T47D Cells. Int. J. Cancer Research, 2, 102
- C. Ma, S. Cai, J. Cui, R. Wang, P. Tu, M. Hattori, and M. Daneshtalab (2005). Cytotoxic Effects of Triterpenes from Apple Peels and Ursolic Acid Derivatives. Eur. J. Med. Chem., 40 (6), 582
- A. Khalaj, N. Adibpour, A. R. Shahverdi, and M. Daneshtalab (2004). Synthesis and Antibacterial Activity of 2-(4-substituted phenyl)-3 (2H)-isothiazolone. Eur. J. Med. Chem., 39 (8), 699